Stereotactic Laser Ablation for Mesial Temporal Lobe Epilepsy: A prospective, multicenter, single-arm study

Area of Science:

• Neurology
• Neurosurgery
• Medical Device Technology

Background:

• Drug-resistant epilepsy presents ongoing treatment challenges.
• Current treatment options have limitations, complicating clinical study design.
• There is a need for robust evidence supporting novel epilepsy therapies.

Purpose of the Study:

• To describe the development of the Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE) study protocol.
• To evaluate the safety and efficacy of the Visualase MRI-Guided Laser Ablation System for temporal lobe epilepsy.
• To establish a study design that satisfies scientific and regulatory requirements for a cleared medical device.

Main Methods:

• Prospective, single-arm, multicenter study.
• Enrollment of up to 150 patients with temporal lobe epilepsy.
• Primary endpoints: seizure freedom (Engel Class I) at 12 months and safety of device-, procedure-, or anesthesia-related adverse events.

Main Results:

• Primary efficacy endpoint: seizure freedom at 12 months post-procedure.
• Primary safety endpoint: incidence of adverse events within 12 months.
• Endpoints will be compared against historical data from anterior temporal lobectomy.

Conclusions:

• The SLATE study protocol aims to provide evidence for stereotactic laser ablation in drug-resistant epilepsy.
• The study design addresses the challenges of evaluating a cleared medical device.
• This approach seeks acceptance from scientific and regulatory bodies for novel epilepsy treatments.